Regulators have approved the world's first Ebola vaccine
Regulators in Europe have approved the first-ever Ebola vaccine and it is immediately going into distribution. The World Health Organisation has prequalified the vaccine, deeming it safe for use globally. According to early reports the vaccine 97.5% effective at preventing the deadly disease. Scientists have been working on this since 2014, ever since the first Ebola outbreak in West Africa.
science health who ebola vaccine
ARSTechnicaRelated Articles
This is when and how the universe is expected to end
It’s not expected to happen anytime soon, but one scientist has calculated when the universe will end. The research, published in the journal Monthly Notices of the Royal Astronomical Society, notes that sometime over the “next few trillion years,” when the universe is dead as we know it, stars will continue to explode, not with a giant bang, but “very, very slowly fizzle. ”
tech space science research astronomy
Nypost
Urea could help make concrete on moon
The European Space Agency said researchers in a recent study it sponsored found that urea, the main organic compound in urine, would make the mixture for a “lunar concrete” more malleable before it hardens into its sturdy final form. “The hope is that astronaut urine could be essentially used as it is on a future lunar base, with minor adjustments to the water content,” study co-author Marlies Arnhof said
moon science europe general-news oddities
Apnews
Coronavirus vaccine begins pre-clinical trials in Australia
Australia's national science agency has begun pre-clinical trials to find a vaccine for the deadly coronavirus. This stage will likely take three months and experts say the vaccine will probably not be ready until late next year. Although the process is going much faster than usual, it is unlikely that the vaccine will be available this year.
science health research economy medicine vaccine death coronavirus quarantine money
Reuters
Coronavirus vaccine may be long-lasting, research suggests
Two recently concluded studies conducted independently by Rome's Lazzaro Spallanzani National Institute for Infectious Diseases and Ancona University Hospital's Department of Biomedical Sciences and Public Health have discovered through genetic sequencing that the coronavirus mutates very slowly, and therefore a vaccine developed for the virus may help inoculate populations for a long time to come.
research italy vaccine department coronavirus covid-19 rome infectious-disease genetic sequencing inoculation mutation ancona-university biomedical-sciences public-health